Developing Botswana Laboratory Capacity in HIV Genomics and HIV Cure

发展博茨瓦纳艾滋病毒基因组学和艾滋病毒治疗实验室能力

基本信息

批准号：
10688320
负责人：
Simani Gaseitsiwe
金额：
$ 10万
依托单位：
BOTSWANA-HARVARD AIDS INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-15 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10688320
关键词：
Acquired Immunodeficiency Syndrome Adolescent Affect Africa South of the Sahara African Anti-Retroviral Agents Area Bioinformatics Biological Assay Boston Botswana Certification Clinical Clinical Research Clinical Trials Collaborations Communities Core Facility Country DNA Data Data Analyses Development Diagnosis Drug resistance Educational workshop Evolution Faculty Flow Cytometry Funding Future Generations Genomic Segment Genomics Genotype Grant HIV HIV-1 HIV-1 vaccine Health Personnel Human Incidence Infant Institution Investigator-Initiated Research Investments Knowledge Laboratories Laboratory Scientists Molecular Molecular Virology Mother-to-child HIV transmission Observational Study Output Patients Persons Pharmaceutical Preparations Prevalence Prevention strategy Public Health Public Health Schools Research Research Personnel Rest SARS-CoV-2 B.1.1.529 Scientist Southern Africa Students Training Training Activity United States National Institutes of Health Universities Vaccine Design Viral Work World Health Organization antiretroviral therapy cohort emerging pathogen epidemiology study experience graduate student implementation science improved interest laboratory experience member mortality next generation sequencing pathogen pathogen genomics pressure professional students programs resistance mutation skills success treatment program university student variants of concern virtual

项目摘要

Project Summary Botswana has been one of the countries most affected by HIV-1 and has always been in the top 3 countries by HIV-1 prevalence for the past 20 years. The country has responded gallantly by providing free antiretroviral therapy (ART) to persons living with HIV-1 (PLWH) in 2002 and an aggressive combination of prevention strategies. This has resulted in reduced HIV-1 incidence and associated mortality and the country was the third globally to reach the UNAIDS 95-95-95 targets of HIV-1 diagnosis, treatment, and viral suppression. Since its inception in 1996, the Botswana Harvard AIDS Institute Partnership (BHP) has conducted investigator-initiated clinical trials, observational and epidemiologic studies, laboratory-based studies, and implementation science research. BHP laboratory also carries out molecular virology research on HIV and this research has been instrumental in molecular characterizing HIV-1 subtype C, which predominates in Botswana and Southern Africa. We draw upon the depth and breadth of the experience gained over more than 2 decades of investigator-initiated research, training, and capacity building to increase access to HIV-1 genomics training. Since 2017, we have invested in implementing pathogen agnostic next- generation sequencing which was critical in the first sequencing of the SARS-CoV-2 Omicron variant of concern in Botswana. Working with our collaborators we have also established cohorts of very early treated infants and adolescents for understanding HIV-1 reservoirs. We, therefore, aim through this application to strengthen BHP in HIV-1 genomics and molecular virology capacity in Botswana and increase access to pathogen genomics in the sub-Saharan Africa region as a center of excellence. The capacity developed here will be crosscutting for virologic studies and will thus be instrumental in BHP lab’s continued diversification into research on other emerging pathogens of global public health interest. To achieve this, we aim to 1) develop and advance BHP as an HIV-1 genomics regional center of excellence. We will leverage the expertise in pathogen genomics developed over the past 20 years to facilitate capacity building by hosting courses in HIV-1 sequencing, bioinformatic analysis, and sequence data interpretation. Building on our collaboration with the University of Botswana, Harvard T.H. Chan School of Public Health (HSPH), and the Ragon Institute of MGH, MIT & Harvard, we will target students and faculty from local and regional Institutions for the training. We will facilitate the development of HIV genomics, make them accessible to local universities and other countries in the region, and 2) To establish HIV-1 Reservoir assays in support of the ongoing and planned HIV-1 cure studies at BHP. We plan to set up assays for the assessment of HIV-1 reservoirs in PLWH in Botswana. Laboratory scientists will be trained on a number of these assays at the collaborator’s laboratory in Boston (Ragon Institute of MGH, MIT & Harvard). We will also train and establish capacity for the bioinformatic analysis for HIV-1 reservoir characterization. 1

项目概要博茨瓦纳一直是受HIV-1影响最严重的国家之一，并且一直位居前3名过去 20 年来，该国通过提供免费服务做出了勇敢的回应。 2002 年对 HIV-1 感染者 (PLWH) 进行抗逆转录病毒治疗 (ART) 以及积极的联合治疗这导致了该国 HIV-1 发病率和相关死亡率的降低。是全球第三个达到 UNAIDS 95-95-95 HIV-1 诊断、治疗和病毒目标的国家自 1996 年成立以来，博茨瓦纳哈佛艾滋病研究所合作伙伴关系 (BHP) 一直在开展艾滋病防治工作。进行研究者发起的临床试验、观察性和流行病学研究、基于实验室的研究必和必拓实验室还开展分子病毒学研究。这项研究对 HIV-1 C 亚型的分子特征研究发挥了重要作用，该亚型我们借鉴了经验的深度和广度。经过 2 多年研究者发起的研究、培训和能力建设而获得的成果，以提高自 2017 年以来，我们投资实施了病原体未知的下一步- 世代测序对于 SARS-CoV-2 Omicron 变体的首次测序至关重要我们还与博茨瓦纳的合作者合作建立了早期治疗队列。婴儿和青少年了解 HIV-1 病毒库。因此，我们的目标是通过此应用来加强 BHP 在 HIV-1 基因组学和分子病毒学方面的实力博茨瓦纳的能力并增加撒哈拉以南非洲地区获得病原体基因组学的机会这里开发的能力将是跨领域的病毒学研究，因此将成为卓越中心。有助于必和必拓实验室持续多元化研究全球公众的其他新兴病原体为了实现这一目标，我们的目标是 1) 开发和推进 BHP 作为 HIV-1 基因组学区域性机构。我们将利用过去 20 年开发的病原体基因组学专业知识。通过举办 HIV-1 测序、生物信息分析和序列课程来促进能力建设数据解读是我们与博茨瓦纳大学、哈佛大学 T.H. Chan 学院合作的基础。公共卫生学院 (HSPH) 以及 MGH、麻省理工学院和哈佛大学的拉根研究所，我们将针对学生和教师我们将促进艾滋病毒基因组学的发展，使当地大学和该地区的其他国家都可以使用它们，并且 2) 建立 HIV-1 库支持必和必拓正在进行和计划中的 HIV-1 治愈研究的检测我们计划建立检测方法。博茨瓦纳 PLWH 中 HIV-1 病毒库的评估将对一些实验室科学家进行培训。我们将在波士顿合作者的实验室（麻省总医院、麻省理工学院和哈佛大学的拉根研究所）进行这些测定。还培训和建立 HIV-1 储存库特征生物信息分析能力。 1